Evogene Ltd., a leading computational biology company targeting to revolutionize life-science product development across several market segments including ag-biologicals, ag-chemicals, human microbiome based therapies and medical cannabis, announced that it will be presenting at the LD 500 investor conference on Wednesday, September 2nd at 9:40 AM ET.
REHOVOT, Israel, Aug. 19, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments including ag-biologicals, ag-chemicals, human microbiome based therapies and medical cannabis, today announced that it will be presenting at the LD 500 investor conference on Wednesday, September 2nd at 9:40 AM ET. Ofer Haviv, Evogene’s President and CEO will be presenting to a live audience.
Register here: https://ld-micro-conference.events.issuerdirect.com/
Investors attending the conference who wish to meet with Mr. Haviv, may contact Evogene’s Investor Relations team at lyonker@edisongroup.com or through the conference’s online meeting platform.
“We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space,” stated Chris Lahiji, Founder of LD.
The LD 500 will take place on September 1st through the 4th.
View Evogene’s profile here: http://www.ldmicro.com/profile/EVGN
About Evogene Ltd.:
Evogene (NASDAQ: EVGN) (TASE: EVGN.TA) is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene established its unique technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
For more information, please visit www.evogene.com
About LD Micro
Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world.
What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space.
The upcoming “500" in September is the Company’s most ambitious project yet, and the first event that is accessible to everyone.
For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.
Forward Looking Statements:
This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. For example, Evogene is using forward-looking statements in this press release when it discusses the end-to-end solutions provided by the system to be developed and the expansion of the Company’s artificial intelligence capabilities and solutions. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the global spread of COVID-19, or the Coronavirus, the various restrictions deriving therefrom and those risk factors contained in Evogene’s reports filed with the applicable securities authorities. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines (including as a result of the effect of the Coronavirus), Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
| Evogene Investor Contact: | US Investor Relations: |
| Rivka Neufeld | Joseph Green |
| Investor Relations and Public Relations Manager | Edison Group |
| T: +972-8-931-1940 | T: +1 646-653-7030 |
| Laine Yonker | |
| Edison Group | |
| T: +1 646-653-7035 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/evogene-to-present-at-ld-500-virtual-conference-301114705.html
SOURCE Evogene; LD Micro
Company Codes: TelAviv:EVGN, NASDAQ-NMS:EVGN
